{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:48:18Z","timestamp":1790354898459,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/bf03345662","type":"journal-article","created":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T10:51:26Z","timestamp":1395485486000},"page":"1119-1123","source":"Crossref","is-referenced-by-count":36,"title":["Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: A metaanalysis from clinical studies"],"prefix":"10.1007","volume":"31","author":[{"given":"F.","family":"Bogazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Manetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Raffaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,22]]},"reference":[{"key":"BF03345662_CR1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/ncpendmet0160","volume":"2","author":"A Colao","year":"2006","unstructured":"Colao A, Di Sarno A, Guerra E, De Leo M, Mentone A, Lombardi G. Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemic men and women. Nat Clin Pract Endocrinol Metab 2006, 2: 200\u201310.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"BF03345662_CR2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 2007, 356: 39\u201346.","journal-title":"N Engl J Med"},{"key":"BF03345662_CR3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007, 356: 29\u201338.","journal-title":"N Engl J Med"},{"key":"BF03345662_CR4","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","volume":"102","author":"RB Rothman","year":"2000","unstructured":"Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotoninergic medications. Circulation 2000, 102: 2836\u201341.","journal-title":"Circulation"},{"key":"BF03345662_CR5","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/CIRCULATIONAHA.107.701367","volume":"116","author":"S Bhattacharyya","year":"2007","unstructured":"Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid heart disease. Circulation 2007, 116: 2860\u20135.","journal-title":"Circulation"},{"key":"BF03345662_CR6","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1742-1241.2008.01779.x","volume":"62","author":"F Bogazzi","year":"2008","unstructured":"Bogazzi F, Buralli S, Manetti L, et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinemia. Int J Clin Pract 2008, 62: 1864\u201369.","journal-title":"Int J Clin Pract"},{"key":"BF03345662_CR7","doi-asserted-by":"crossref","unstructured":"Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy in not associated with valvular heart disease in patients with prolactinomas. Pituitary 2008, July 2 [Epub ahead of print]; doi: 10.1007\/s11102-008-0134-2.","DOI":"10.1007\/s11102-008-0134-2"},{"key":"BF03345662_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-08-0213","volume":"159","author":"P Lancellotti","year":"2008","unstructured":"Lancellotti P, Livadariu E, Markov M, et al. Cabergoline and risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008, 159: 1\u20135.","journal-title":"Eur J Endocrinol"},{"key":"BF03345662_CR9","doi-asserted-by":"crossref","unstructured":"Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JAH. Valvular heart disease and the use of cabergoline forthe treatment of prolactinoma. Clin Endocrinol 2008, Oct 21 [Epub ahead of print]; doi: 10.1111\/j.1365-2265.2008.03458.x.","DOI":"10.1111\/j.1365-2265.2008.03458.x"},{"key":"BF03345662_CR10","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","volume":"93","author":"M Kars","year":"2008","unstructured":"Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008, 93: 3348\u201356.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345662_CR11","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/EJE-08-0365","volume":"159","author":"A Wakil","year":"2008","unstructured":"Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008, 159: R11\u20134.","journal-title":"Eur J Endocrinol"},{"key":"BF03345662_CR12","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","volume":"93","author":"A Colao","year":"2008","unstructured":"Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008, 93: 3777\u201384.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345662_CR13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4065\/78.6.730","volume":"78","author":"CM Flowers","year":"2003","unstructured":"Flowers CM, Racoosin JA, Lu SL, Beitz JG. The US food and Drugs Administration\u2019s registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003, 78: 730\u20131.","journal-title":"Mayo Clin Proc"},{"key":"BF03345662_CR14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","volume":"16","author":"WA Zoghbi","year":"2003","unstructured":"Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003, 16: 777\u2013802.","journal-title":"J Am Soc Echocardiogr"},{"key":"BF03345662_CR15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7: 177\u201388.","journal-title":"Control Clin Trials"},{"key":"BF03345662_CR16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","volume":"57","author":"LW Fitzgerald","year":"2000","unstructured":"Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000, 57: 75\u201381.","journal-title":"Mol Pharmacol"},{"key":"BF03345662_CR17","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/mds.21639","volume":"22","author":"G Simonis","year":"2007","unstructured":"Simonis G, Fuhrmann JT, Strasser RH. Meta-analysis of heart valve abnormalities in Parkinson\u2019s disease patients treated with dopamine agonists. Mov Disord 2007, 22: 1936\u201342.","journal-title":"Mov Disord"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03345662.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03345662\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03345662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T04:00:58Z","timestamp":1746158458000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03345662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["BF03345662"],"URL":"https:\/\/doi.org\/10.1007\/bf03345662","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}